Evaluating the effectiveness of endocrinology learning interventions to support better clinical practice. Endocrinology requires ongoing education to keep pace with evolving treatment guidelines and long-term disease management strategies. But how effective is endocrinology-focused education in driving meaningful learning outcomes? nuaxia analysed behavioural data from endocrinology education activities to answer this question. Through detailed pre- and post-education analysis, nuaxia assessed changes in knowledge and competence, providing data-backed insights into the real-world impact of endocrinology education programmes. Key Findings at a Glance 87% of Participants Improved Their Scores Nearly nine out of ten participants showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 63% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 63% improved 25% remained stable Only 12% saw a decrease These insights show that personalised, structured education enables HCPs to progress meaningfully from any starting point. 32% Achieved the Top Score After Medical Education Activity Nearly a third of participants reached the top performance group, highlighting the effectiveness of CME activities in supporting HCP learning. Score Distribution: Before vs. After Baseline Scores: Most participants began in the Average (42.7%) or High (42.7%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (46.5%) or Top (32.0%) categories. This shows that impactful medical education doesn’t just inform - it transforms. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change The benefits reach far beyond learners, fostering measurable improvements in global patient care. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Examining the impact of dermatology education on knowledge application and patient care quality. Dermatology education must address a broad spectrum of conditions, from chronic inflammatory diseases to complex diagnostic challenges. nuaxia analysed behavioural data from dermatology-focused medical education activities to evaluate how effectively these programmes support healthcare professional learning. By assessing changes in knowledge and competence following educational interventions, this analysis offers objective insights into the value of dermatology education and its role in improving clinical understanding. Key Findings at a Glance 97% of Participants Improved Their Scores Nearly all HCPs showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 79% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 79% improved 19% remained stable Only 2% saw a decrease This highlights how education programmes can support HCPs’ growth, regardless of their initial level of knowledge or experience. 44% Achieved the Top Score After Medical Education Activity 44% of participants reached the top performance group, showing that CME activities are effectively supporting HCPs in achieving high performance. Score Distribution: Before vs. After Baseline Scores: Most participants began in the Average (51.6%) or High (33.9%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the Top (43.5%) or High (40.4%) categories. The results underscore that medical education’s true value lies in its ability to change behaviour and outcomes, not just impart information. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change This advancement for HCPs directly contributes to better healthcare outcomes on a global scale. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Analysing how targeted haematology training enhances understanding and informs treatment decisions. Haematology education plays a vital role in supporting healthcare professionals managing complex and often life-threatening conditions. But how effective are current educational approaches in this field? nuaxia analysed behavioural data from haematology-focused education activities to evaluate their impact on learner knowledge and competence. Using data-driven methodologies, this analysis tracks changes in learning outcomes before and after educational interventions, providing robust evidence of how haematology education contributes to improved understanding and professional development. Key Findings at a Glance 93% of Participants Improved Their Scores With 93% of participants showing measurable improvements, these results demonstrate the clear impact of our educational programmes on HCP performance. 72% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 72% improved 23% remained stable Only 5% saw a decrease The results underline how effective education accommodates diverse learning levels and fosters ongoing growth. 36% Achieved the Top Score After Medical Education Activity Over a third of participants progressed to the top performance group, underscoring the measurable impact of CME on professional learning outcomes. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (41.5%) or Average (39.2%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (45.5%) or Top (36.6%) categories. These findings illustrate that education in medicine is not merely informative; it inspires measurable improvements. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change These gains for HCPs ultimately translate into higher-quality care for patients worldwide. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Role of Starting Knowledge in Shaping Competency Growth Medical education builds on what learners already know, and starting knowledge can shape how much they gain. Nuaxia analysed pre- and post-test scores across Moore’s Levels 3a, 3b, and 4 to see how baseline competence drives learning growth. The pattern is clear: learners with lower starting knowledge, especially at Level 3a, make the biggest gains, while those starting higher improve less. Even across different levels, the trend holds. Which means that baseline knowledge is a strong guide to where educational effort will have the most impact. By visualising this relationship, Nuaxia shows how understanding learners’ starting points lets educators target interventions to maximise growth and meaningful knowledge gains across all Moore’s Levels. Key Findings at a Glance Lower baseline → greater growth: Learners in Moore’s Level 3a, with the lowest pre-test scores, showed the largest increases in post-test performance. Moderate baseline → steady gains: Level 3b learners started higher and still made substantial improvements, though smaller than 3a. Higher baseline → smaller gains: Level 4 learners, starting with the highest pre-test scores, had the least room to improve. Baseline predicts nearly 50% of variation: Regression analysis shows R² values around 0.47–0.56 across levels, meaning pre-test scores explain almost half of the differences in learning gains. Ceiling effect is evident: The higher the initial knowledge, the smaller the potential improvement, highlighting the importance of personalised learning approaches. Implication for educators: Tailoring interventions to learners’ starting points maximises growth where it is most needed and supports meaningful learning across all Moore’s Levels. Why These Results Matter These results show that baseline knowledge is a powerful predictor of learning gains across Moore’s Levels. By understanding where learners start, educators can design targeted interventions that maximise growth. In doing so, it ensures resources are focused where they will have the greatest impact and help all learners achieve meaningful knowledge and competency improvements. Methodology The analysis was based on: Pre and Post Assessment total activity score (Moore’s Level 3a, 3b and 4) X axis = Pre-Test (%), Y axis = Absolute % Increase Regression Analysis Learners’ pre- and post-assessment scores (Moore’s Levels 3a, 3b, and 4) were analysed, with the X-axis representing pre-test scores (%) and the Y-axis showing absolute percentage increase. Regression analysis quantified how baseline knowledge predicts learning gains, highlighting the relationship between starting competence and improvement. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. By using baseline knowledge to guide interventions, educators can personalise learning experiences, maximise impact, and ensure that learners at all Moore’s Levels achieve meaningful gains. Nuaxia’s analytics capabilities make it easier to measure, understand, and optimise educational outcomes for future programmes. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Quantifying How Baseline Knowledge Influences Learning Gains in Medical Education Medical education builds on what learners already know, and initial knowledge can dramatically shape how much they gain. By analysing both pre- and post-test scores across multiple interventions, Nuaxia quantified how baseline competence predicts learning growth. The data reveal a clear pattern: the lower the starting knowledge, the greater the improvement, while higher baseline scores leave less room for growth. Through regression analysis and scatter plot visualisation, we show that nearly 50% of the variation in learning gains is explained by pre-test performance. These insights highlight the value of targeting educational strategies to learners’ starting points, ensuring interventions maximise growth where it’s most needed and support all learners in achieving meaningful knowledge gains. Key Findings at a Glance Lower baseline → greater growth: Learners with lower pre-test scores showed the largest increases in post-test performance. Higher baseline → smaller gains: Learners starting with higher pre-test scores had less room to improve. Baseline predicts nearly 50% of variation: Regression analysis shows R² = 0.476, meaning pre-test scores explain almost half of the differences in learning gains. Ceiling effect is evident: The higher the initial knowledge, the smaller the potential improvement — highlighting the importance of personalised learning approaches. Implication for educators: Tailoring interventions to learners’ starting points maximises growth where it’s most needed. Why These Results Matter Baseline knowledge strongly shapes learning outcomes: those starting lower show the greatest gains, while higher-performing learners have less room to improve. These results highlight the value of tailoring education to starting competence, ensuring all learners reach their full potential. By quantifying this relationship, Nuaxia provides actionable insights for optimising medical education. Methodology The analysis was based on: Pre and Post Assessment total activity score (Moore’s Level 3a, 3b and 4) X axis = Pre-Test (%), Y axis = Absolute % Increase Regression Analysis Learners’ pre- and post-assessment scores (Moore’s Levels 3a, 3b, and 4) were analysed, with the X-axis representing pre-test scores (%) and the Y-axis showing absolute percentage increase. Regression analysis quantified how baseline knowledge predicts learning gains, highlighting the relationship between starting competence and improvement. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. For organisations planning a new CME programme or aiming to measure the impact of existing initiatives, Nuaxia’s database and analytics capabilities can help deliver meaningful outcomes. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Exploring evidence-based approaches to immunology education and their effectiveness in knowledge retention. Immunology underpins many of today’s most significant therapeutic advances, from biologics to personalised medicine. As the field evolves, the effectiveness of immunology education becomes increasingly important. nuaxia conducted a detailed analysis of behavioural data from immunology education activities to assess how learning interventions shape professional competence. By examining pre- and post-education performance, nuaxia’s analysis delivers objective insights into how immunology education influences knowledge retention and clinical understanding, offering a clearer view of educational impact in this rapidly advancing discipline. Key Findings at a Glance 93% of Participants Improved Their Scores Nearly all participants achieved improvements in knowledge and competence, underscoring the tangible benefits of our CME initiatives. 69% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 69% improved 29% remained stable Only 2% saw a decrease This shows that structured medical education adapts to HCPs’ starting points while driving measurable development. 41% Achieved the Top Score After Medical Education Activity Notably, 41% of participants reached the top performance group, showing that CME activities are helping a significant portion of HCPs achieve high performance. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (48.4%) or High (35.6%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (45.8%) or Top (41.4%) categories. This shows that well-designed medical education can transform professional performance, not just understanding. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change Not only do HCPs gain from this education, but patients also experience improved outcomes globally. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

In the fast-evolving world of healthcare, continuous medical education (CME) is vital. But how effective is it really? At nuaxia, we analysed tens of thousands of behavioural data points across over 350 global medical education activities, and the results are clear: high-quality education is making a measurable difference. The Power of Data in Understanding Medical Education Outcomes Using advanced data science techniques, including silhouette scoring and participant clustering, nuaxia evaluated the knowledge and competence changes amongst healthcare professionals (HCPs) before and after medical education interventions. With a large dataset spanning 170 specialisms in over 50 countries, this analysis provides robust, objective evidence of educational impact. Key Findings at a Glance 94% of Participants Improved Their Scores Nearly all HCPs showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 74% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 74% improved 23% remained stable Only 3% saw a decrease This shift underlines how well-structured education meets HCPs where they are and helps them grow, regardless of the starting point. 44% Achieved the Top Score After Medical Education Activity Perhaps most impressively, nearly half of all participants reached the top performance group, indicating that CME activities are not only raising the bar but also helping HCPs reach it. Score Distribution: Before vs. After Baseline Scores: Most participants began in the Average (45.3%) or High (41.1%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (42.9%) or Top (43.5%) categories. This shows that impactful medical education doesn’t just inform - it transforms. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change This benefits not only HCPs but ultimately improves patient outcomes on a global scale. Our Methodology The analysis was based on: 350+ educational activities 10 therapeutic areas 170+ medical specialties 50+ countries Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Funding round will support development of lead targeted alpha therapy ADVC001 in metastatic prostate cancer and expand Lead-212 manufacturing capabilities. AdvanCell has raised $315 million in a Series D financing round backed by major pharmaceutical players including Sanofi and Eli Lilly, as the radiopharmaceutical developer advances its targeted alpha therapy pipeline towards late-stage clinical development. The financing, led by Ally Bridge Group and co-led by Alpha Wave, will support the continued development of AdvanCell’s lead programme, ADVC001, a Lead-212-based radiopharmaceutical currently being evaluated in metastatic prostate cancer. The latest investment builds on growing industry confidence in AdvanCell’s approach to targeted alpha therapies, following Sanofi’s venture arm co-leading the company’s $112 million Series C financing in 2025. The move also follows a strategic collaboration announced between AdvanCell and Lilly, combining AdvanCell’s Lead-212 production capabilities and radionuclide infrastructure with Lilly’s drug development expertise to accelerate the development of targeted alpha therapies. Advancing a New Generation of Radiopharmaceuticals Radiopharmaceuticals have emerged as a major area of oncology investment, using radioactive isotopes attached to targeting molecules to selectively deliver cancer-killing radiation directly to tumour cells. AdvanCell’s technology platform is focused on the scalable and automated production of Lead-212, a promising isotope for targeted alpha therapy applications. The company’s lead candidate, ADVC001, is a Lead-212 PSMA-targeted alpha therapy designed for patients with metastatic prostate cancer. The therapy is currently being evaluated in a Phase II clinical trial, with the latest funding expected to support progression towards Phase III development. AdvanCell is also using the financing to expand its isotope manufacturing infrastructure in the US, addressing one of the key challenges facing the broader radiopharmaceutical sector: reliable, scalable production capacity. Targeting Challenges in Existing Radioligand Therapies Current PSMA-targeted radioligand therapies have demonstrated clinical benefits in prostate cancer, but challenges remain around treatment resistance, tolerability and optimising dosing strategies. AdvanCell believes targeted alpha therapy could help address some of these limitations by delivering highly potent radiation directly to cancer cells while reducing exposure to surrounding healthy tissue. The company’s approach uses Lead-212, which releases alpha particles capable of causing significant tumour cell damage over a short range. This targeted mechanism could potentially improve the therapeutic window compared with broader radiation approaches. Pharma Interest in Radiopharmaceutical Infrastructure The latest financing highlights increasing pharmaceutical interest in radiopharmaceutical platforms, particularly those with the manufacturing capabilities required to support commercial-scale development. “The most enduring healthcare companies combine breakthrough science with the infrastructure and expertise to repeatedly develop new medicines,” said Nik Economopoulos, director of life sciences investments at Alpha Wave. “We believe AdvanCell is building that kind of generational company, with the platform, manufacturing capabilities and pipeline to unlock the full potential of targeted alpha therapies.” Expanding Investor Support Alongside Sanofi and Lilly, the Series D financing included participation from new investors including Bain Capital Life Sciences, Fidelity Management & Research Company, T. Rowe Price Associates, Eventide Asset Management and Velosity Capital. Existing investors including Morningside, SV Health Investors, Abingworth, SymBiosis, Tenmile, Brandon Capital, Piper Heartland, Catalio Capital Management, Proto Axiom and Time BioVentures also participated. With ADVC001 approaching later-stage development and investment accelerating across the radiopharmaceutical landscape, AdvanCell is positioning itself at the intersection of oncology innovation and critical manufacturing infrastructure. The company’s progress reflects a wider industry shift towards precision cancer therapies designed not only around new biological targets, but also around the ability to manufacture and deliver increasingly complex treatments at scale. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Strong private investment signals renewed confidence in the UK life sciences sector, but public markets remain a challenge. The UK biotech sector continued its funding recovery in 2026, with investment reaching a five-year high during the second quarter as venture capital activity surged across the industry. New figures from the UK BioIndustry Association (BIA) show that UK biotech companies secured £2.11 billion ($2.84 billion) in equity financing during Q2 2026, including a record £2.05 billion in venture capital investment. The latest figures build on the positive momentum seen earlier in the year and highlight renewed investor confidence in UK life sciences following a more challenging funding environment in recent years. “This quarter shows continued improvement in funding confidence and deal flow right across the UK biotech sector,” said Chris Molloy, chief executive of the BIA. “Its major headline is the strongest single quarter for UK life sciences venture funding in the last five years.” Isomorphic Labs drives record-breaking quarter The headline figure was heavily influenced by the major fundraising round completed by Isomorphic Labs. The Alphabet-backed company raised £1.6 billion in a Series B financing round in May 2026, representing one of the largest biotech funding events in the UK’s history. However, even excluding Isomorphic Labs’ contribution, the sector still demonstrated meaningful growth. UK biotech companies raised £498 million in venture capital during Q2 2026, compared with £279 million during the same period in 2025. The BIA said the figures demonstrate improving confidence among investors and continued appetite for innovation-led biotech companies. Seed investment remains resilient While large late-stage financings dominated headlines, early-stage investment also remained steady. The BIA reported that seed investment remained resilient during the second quarter, with eight seed financings completed during the period. The organisation highlighted continued institutional support for the sector as a positive indicator for future biotech pipeline development. Early-stage funding remains critical for companies developing novel therapeutics, platforms and technologies, where significant investment is required before clinical validation and commercial opportunities emerge. UK strengthens position as Europe’s leading biotech funding market The UK continued to outperform other European biotech markets during the quarter. UK venture capital investment accounted for 61% of all European biotech venture funding in Q2 2026, compared with 57% during Q1. The BIA said the figures reinforce the UK’s position as Europe’s leading destination for biotech investment. For biotech companies seeking capital to advance clinical programmes, expand research capabilities or scale manufacturing operations, the latest funding data highlights the continued attractiveness of the UK ecosystem. Public markets remain the missing piece Despite strong private investment activity, the BIA warned that public markets have yet to recover at the same pace. No UK biotech companies completed an initial public offering (IPO) during 2026, highlighting the ongoing gap between private financing strength and public market support. “UK public markets need to recognise, cover and return to backing our sector and private momentum must be joined by robust, public sector-managed, investor-advised translational funding,” Molloy said. The lack of IPO activity remains a challenge for biotech companies looking to transition from venture-backed growth businesses into publicly traded organisations. What does this mean for UK biotech? The latest funding figures provide a positive signal for the UK life sciences sector, showing that investor appetite is returning for innovative biotech companies. Strong venture capital flows could help accelerate the development of new medicines, support emerging platforms such as artificial intelligence-driven drug discovery, and strengthen the UK’s role in global pharmaceutical innovation. However, maintaining this momentum will require progress beyond private investment, with improved public market confidence needed to support companies through later stages of growth. For UK biotech, 2026 is shaping up as a year of renewed optimism — but converting funding momentum into long-term industry growth will depend on continued support across the entire innovation ecosystem. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The once-daily tablet provides a new oral option for reducing LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia. The FDA has approved Lipfendra (enlicitide) as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia. As the first oral therapy to inhibit PCSK9, Lipfendra expands treatment choice beyond the injectable PCSK9 therapies previously available. Field Content Alert Type Drug Approval Drug Name Lipfendra Indication Reduction of LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia Therapy Area(s) Cardiology Geography US (FDA) What Changed The FDA approved Lipfendra (enlicitide) on 16 July 2026 as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia. It is the first orally administered drug approved to inhibit PCSK9. Clinical Relevance Provides a once-daily oral PCSK9 treatment option for adults requiring LDL-cholesterol reduction, expanding choice beyond injectable PCSK9 therapies. Source Link FDA approval notice. Date 16 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The designation supports development of a one-time investigational gene therapy designed to address the underlying genetic cause of a rare form of dilated cardiomyopathy. The FDA has granted orphan drug designation to Affinia Therapeutics’ AFTX-201 for the treatment of BAG3-associated dilated cardiomyopathy. The designation provides development incentives for the investigational AAV gene therapy, which is being studied in the Phase 1/2 UPBEAT trial and has not received marketing approval. Field Content Alert Type Regulatory Designation – Orphan Drug Drug Name AFTX-201 Indication Treatment of BAG3-associated dilated cardiomyopathy Therapy Area(s) Cardiology; Rare disease Geography US (FDA) What Happened Affinia Therapeutics announced on 22 July 2026 that the FDA had granted orphan drug designation to AFTX-201 for BAG3-associated dilated cardiomyopathy. AFTX-201 is an investigational AAV gene therapy designed to deliver a functional BAG3 transgene through a single intravenous infusion; the designation is not a marketing approval. Why It Matters Orphan drug designation provides incentives intended to support development of treatments for rare diseases, including potential tax credits, exemption from certain FDA application fees and seven years of market exclusivity if the product is later approved. It does not establish that AFTX-201 is safe or effective. Supporting Context BAG3-associated dilated cardiomyopathy is caused by genetic changes that reduce BAG3 protein in heart cells and can lead to early-onset progressive heart failure. No approved treatment currently addresses the underlying genetic mechanism, while AFTX-201 is being evaluated in the recruiting Phase 1/2 UPBEAT trial. Key Takeaway The designation provides regulatory and development support for AFTX-201 but does not constitute FDA approval of the therapy. What to Watch Safety, tolerability and preliminary efficacy findings from the UPBEAT trial, together with any subsequent FDA development or review milestones. Primary Source Affinia Therapeutics’ official announcement Relevant Date 22 July 2026 — company announcement date Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The spin-out creates a dedicated US oncology company to raise capital and advance Lupin’s PRMT5 and SOS1 programmes through global clinical development. Lupin has granted Kaveri Therapeutics exclusive, perpetual licences to two clinical-stage oncology programmes—LNP7457 and LNP8701—in exchange for an 82.2% equity stake, with the assets valued at $1.6 million. The arrangement is intended to accelerate their development through an independently managed oncology company that will seek external funding for global clinical trials. Field Content Alert Type Deal Companies Lupin Inc., the wholly owned US subsidiary of Lupin Limited, and Kaveri Therapeutics Deal Type Strategic spin-out and exclusive perpetual licensing agreement involving an 82.2% equity stake Asset or Company LNP7457, a PRMT5-targeting programme, and LNP8701, a SOS1-targeting programme Therapy Area(s) Oncology Technology or Modality Targeted small-molecule oncology therapies Deal Value The two licensed programmes were valued at $1.6 million. Lupin received 332,000 common shares representing an 82.2% stake in Kaveri and will also provide seed funding, the amount of which was not disclosed. Development Stage Clinical-stage programmes in early clinical development Geography US-based transaction with planned global clinical development What Happened Lupin granted Kaveri exclusive, perpetual licences to LNP7457 and LNP8701 in exchange for an 82.2% equity stake. The transaction was completed on 20 July 2026, and Kaveri will assume responsibility for advancing the programmes through global clinical trials. Background Kaveri was incorporated in Delaware in May 2026 as a clinical-stage oncology company focused on solid tumours, including lung, pancreatic, ovarian and CNS-related cancers. Lupin reported that LNP7457 and LNP8701 presented positive clinical data at the 2025 and 2026 ASCO meetings, respectively. Strategic Rationale The structure places the two programmes within a dedicated, independently managed oncology company that can raise external capital and focus on global clinical development, while Lupin retains a majority equity interest in their future progress. Why It Matters The deal gives the programmes a specialised development vehicle and access to additional financing without Lupin relinquishing its majority economic interest. It also expands Kaveri’s pipeline across two targeted mechanisms relevant to difficult-to-treat solid tumours. Potential Impact Successful fundraising could support broader global trials and biomarker-driven development of the PRMT5 and SOS1 programmes, although their eventual clinical and commercial value will depend on future trial results. Key Takeaway Lupin is using a majority-owned spin-out to pursue external funding and focused clinical development for two targeted oncology assets. What to Watch Kaveri’s planned capital raise, the design and progression of global clinical trials, future data from both programmes and any additional financing or partnership arrangements. Source Link Lupin regulatory filing and accompanying company press release Deal Date 21 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com